{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3.0","upperLimit":"6.2","value":"4.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"}],"units":"Participants"}],"description":"IRC assessed TTP per 2016 IMWG criteria: Duration from start of study treatment until PD or death due to PD (per IRC), whichever occurred first. Progressive disease (PD): Increase of 25% from lowest confirmed response value in 1 or more of the following criteria: Serum M-protein with absolute increase of \\>= 0.5 g/dL; Serum M-protein increase \\>=1 g/dL if the lowest M-component was \\>= 5 g/dL; Urinary M-protein (absolute increase must be \\>= 200 mg/24 hours). Analysis was performed using Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants who previously had received more than 3 anti-MM regimens and had penta-exposed, triple class-refractory MM (i.e. previously treated with lenalidomide, pomalidomide, bortezomib, carfilzomib, and daratumumab, and refractory to prior treatment with glucocorticoids, an IMiD, a PI, and the anti-CD38 mAb daratumumab) received, selinexor 80 mg PO plus low-dose dexamethasone 20 mg Sd twice-weekly on Days 1 and 3 until disease progression, death, or unacceptable toxicity (maximum duration of approximately 17 months).","id":"OG000","title":"Part 2"}],"paramType":"MEDIAN","populationDescription":"mITT population consisted of Part 2 participants with penta-refractory MM who met all eligibility criteria and received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From start of study treatment to progression of disease or death, whichever occurred first (maximum duration of 17 months)","title":"Part 2: Time to Progression (TTP) Per IMWG as Assessed by IRC","type":"SECONDARY","unitOfMeasure":"Months"}